All In Biotech

Drug Trial Radar · NCT07266805

Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Oct 16, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Pharvaris Netherlands B.V.Industry
Sponsor type
Industry
First posted
Dec 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant soft capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.

Conditions

  • Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)

Interventions

  • DeucrictibantDrug

    Part 1: Deucrictibant 40 mg extended-release tablet for once daily oral use

  • PlaceboDrug

    Part 1: Placebo Comparator tablet for once daily oral use

  • DeucrictibantDrug

    Part 2: Deucrictibant 20 mg soft capsule oral use

  • PlaceboDrug

    Part 2: Placebo Comparator soft capsule oral use

  • DeucrictibantDrug

    Part 3: Deucrictibant 20 mg soft capsule oral use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Time-normalized number of Investigator-confirmed AAE-C1INH attacks during Treatment PhaseTime frame: 12 weeks
  2. Part 2: Time to symptom relief, Patient Global Impression of Change (PGI-C) rating of at least "better"Time frame: 12 hours post-treatment
  3. Part 3: Incidence of treatment-emergent adverse events (TEAEs), treatment-emergent adverse events of special interest (AESIs), and serious adverse events (SAEs)Time frame: Through study termination, an average of 36 weeks
  4. Part 3: Number of participants with clinically significant changes from baseline in Hematology parametersTime frame: Through study termination, an average of 36 weeks
  5. Part 3: Number of participants with clinically significant changes from baseline in Urinalysis parametersTime frame: Through study termination, an average of 36 weeks
  6. Part 3: Number of participants with clinically significant changes from baseline in Biochemistry parametersTime frame: Through study termination, an average of 36 weeks
  7. Part 3: Number of participants with clinically significant changes from baseline in vital signsTime frame: Through study termination, an average of 36 weeks
  8. Part 3: Number of participants with clinically significant changes from baseline in physical examinationsTime frame: Through study termination, an average of 36 weeks
  9. Part 3: Number of participants with clinically significant changes in electrocardiogram (ECG)Time frame: Through study termination, an average of 36 weeks

Locations

32 sites in 16 countries. Site status is shown where the registry gives one.

  • Study Site

    San Diego, California · Recruiting

  • Study Site

    Walnut Creek, California · Recruiting

  • Study Site

    St Louis, Missouri · Recruiting

  • Study Site

    Hershey, Pennsylvania · Recruiting

  • Study Site

    Clayton, Australia · Recruiting

  • Study Site

    Vienna, Austria · Recruiting

  • Study Site

    Sofia, Bulgaria · Recruiting

  • Study Site

    Edmonton, Canada · Recruiting

  • Study Site

    Grenoble, France · Recruiting

  • Study Site

    Lille, France · Recruiting

  • Study Site

    Paris, France · Recruiting

  • Study Site

    Berlin, Germany · Recruiting

  • Study Site

    Frankfurt am Main, Germany · Recruiting

  • Study Site

    Munich, Germany · Recruiting

  • Study Site

    Budapest, Hungary · Recruiting

  • Study Site 1

    Milan, Italy · Recruiting

  • Study Site 2

    Milan, Italy · Recruiting

  • Study Site 3

    Milan, Italy · Recruiting

  • Study Site

    Padova, Italy · Recruiting

  • Study Site

    Roma, Italy · Recruiting

  • Study Site

    Amsterdam, Netherlands · Recruiting

  • Study Site

    Auckland, New Zealand · Recruiting

  • Study Site

    Krakow, Poland · Recruiting

  • Study Site

    Madrid, Spain · Recruiting

  • Study Site

    Basel, Switzerland · Recruiting

  • Study Site

    Ankara, Turkey (Türkiye) · Recruiting

  • Study Site

    Bristol, United Kingdom · Recruiting

  • Study Site

    Cambridge, United Kingdom · Recruiting

  • Study Site

    Leicester, United Kingdom · Recruiting

  • Study Site

    London, United Kingdom · Recruiting

  • Study Site

    Newcastle upon Tyne, United Kingdom · Recruiting

  • Study Site

    Plymouth, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.